




Medicines & Healthcare products  
Regulatory Agency




# Inspection of cross contamination controls in shared facilities

Graeme McKilligan, UK, MHRA.




# Key steps expected after HBEL determined


Sites need to consider the content of an HBEL assessment and/or if using a 'traditional approach' understand the hazard, context and extent of the HBEL



Sites should use a practical common sense approach - what the exposure limit would equate to in terms of contamination left in equipment at batch and unit dose contact points or transferred via air borne or other contact. Consider the significance of this and how easily such a quantity could be missed or transferred, particularly should errors occur.




Sites should have initiated a risk assessment using the relative hazards/risks identified from HBEL to determine the level of detail required – matrix approach may be relevant to negate the need for separate RAs for each product.




Based on the hazard and risk, justification should be recorded for the extent and content of the risk assessment.

The process train, current or proposed controls should be documented in appropriate detail in the risk assessment. Opportunities for failure in controls should be recorded and further controls identified as necessary. The assessment should consider the effectiveness of controls and not assume they are effective.




Where inherent controls such as the pharmaceutical form are considered to be mitigating factors to the hazard then this should be recorded and justified.



Clear, concise risk assessment expected with robust evidence based justification for suitability of controls. Controls in place should be clearly recorded along with justification for suitability. 'We have a procedure and have done it this way for years' not regarded as suitable justification without supporting evidence.

Identify clearly where specific separation or dedicated parts, equipment or area is required based on an unreasonable risk of failure or difficulty to control otherwise.



Specific processes expected with greater detail and control where hazards are greater and /or remaining risk subject to error/failure:

Cross contamination control assessment

Setting cleaning and control limits

Risk management/development of organisational and technical control measures

How to develop cleaning methods (expecting to include use of drawings of equipment with additional physical examination)

Cleaning validation

Training

Ongoing verification options

Quality system management, data gathering and periodic review.

Clear evidence of ongoing control

New product introduction controls

# © Crown Copyright 2017

## **About copyright**

All material created by the Medicines and Healthcare products Regulatory Agency, including materials featured within these MHRA presentation notes and delegate pack, is subject to Crown copyright protection. We control the copyright to our work (which includes all information, database rights, logos and visual images), under a delegation of authority from the Controller of Her Majesty's Stationery Office (HMSO).

The MHRA authorises you to make one free copy, by downloading to printer or to electronic, magnetic or optical storage media, of these presentations for the purposes of private research, study and reference. Any other copy or use of Crown copyright materials featured on this site, in any form or medium is subject to the prior approval of the MHRA.

Further information, including an application form for requests to reproduce our material can be found at [www.mhra.gov.uk/crowncopyright](http://www.mhra.gov.uk/crowncopyright)

## **Material from other organisations**

The permission to reproduce Crown copyright protected material does not extend to any material in this pack which is subject to a separate licence or is the copyright of a third party. Authorisation to reproduce such material must be obtained from the copyright holders concerned.